FREE Case Evaluation: 1-888-887-3117
The latest news on roundup settlement shows a litigation landscape that's far from over, with massive jury verdicts and ongoing negotiations that could impact tens of thousands of claims still pending.
Key Updates You Need to Know:
• 170,000 total claims filed as of April 2025
• $11 billion already paid by Bayer to settle ~100,000 cases
• 4,400 cases still pending in federal court (MDL)
• $2.1 billion verdict awarded in Georgia (March 2025)
• $150,000 average payout estimated for settled claims
• Potential bankruptcy of Monsanto unit being explored by Bayer
Since Bayer acquired Monsanto in 2018 for $63 billion, the company has faced an avalanche of lawsuits claiming that Roundup's active ingredient, glyphosate, causes non-Hodgkin's lymphoma and other cancers. While the International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans" in 2015, the EPA maintains it's safe when used as directed.
The stakes couldn't be higher. Recent jury verdicts have reached into the billions, with a Georgia jury awarding nearly $2.1 billion to a single plaintiff in March 2025. Meanwhile, Bayer has set aside $5.9 billion for pending cases and is pursuing multiple strategies to end the litigation—including potential Supreme Court intervention and even bankruptcy protection for its Monsanto division.
What makes this moment critical is that statute of limitations windows are closing for many potential claimants, while settlement negotiations continue behind the scenes. If you've used Roundup and developed cancer, understanding these developments could be the difference between receiving compensation and missing your window entirely.
I'm Tim Burd, founder of Justice Hero, and I've helped thousands of people steer complex mass tort litigation over the past decade. My team and I stay on top of the latest news on roundup settlement developments to ensure people understand their rights and options in this evolving legal landscape.
Right now, the Roundup litigation world feels like a tale of two very different stories. On one side, you have massive jury verdicts that make headlines—like the jaw-dropping $2.1 billion Georgia verdict from March 2025. On the other side, you have the reality that most people who settle get around $150,000 on average.
Here's where things stand as of April 2025: 170,000 people have filed Roundup claims across the country. Bayer has already written checks totaling $11 billion to settle about 100,000 cases. But don't think this story is over—4,400 cases are still pending in federal court, and thousands more are working their way through state courts.
The latest news on roundup settlement developments show just how unpredictable this litigation has become. That Georgia man who won $2.1 billion? His case went to trial instead of settling. Meanwhile, a Philadelphia jury awarded $78 million to another plaintiff in late 2024. These verdicts dwarf the typical settlement amounts, which explains why some people choose to roll the dice in court.
Bayer isn't sitting idle. They've set aside $5.9 billion in legal reserves for pending cases and are exploring some pretty dramatic moves. Word is they're even considering Chapter 11 bankruptcy protection for their Monsanto division—a move that could pause all lawsuits and force everyone into a court-supervised settlement process.
What makes this situation particularly interesting is the contrast between what juries award and what appeals courts allow to stand. That massive Pennsylvania verdict of $2.25 billion? It got chopped down to $400 million on appeal. Still a lot of money, but it shows how these cases can change dramatically as they move through the system.
For anyone trying to understand the science behind these cases, the EPA's official stance on glyphosate safety provides the government's perspective—which often differs significantly from what plaintiffs argue in court.
The numbers tell an interesting story about where this litigation is heading. While 4,415 cases remain in federal court, the real action has shifted to state courthouses across America. Most new cases are being filed in state courts, where plaintiffs' lawyers believe they'll find more sympathetic juries.
This shift has created what some legal experts call "venue shopping"—basically, lawyers filing cases in counties known for big jury awards. Missouri, Pennsylvania, and California have become hotspots for Roundup cases, with some counties seeing hundreds of new filings.
The 2020 block settlement resolved about 100,000 claims, but many potential claims got left out. Some people missed filing deadlines. Others couldn't prove enough exposure to Roundup. Still others had cancer types that didn't qualify under the settlement criteria.
As of late 2024, 114,000 of the roughly 177,000 total claims had been resolved or deemed ineligible. That leaves a substantial number still fighting for compensation—and new claims are still being filed as people find their cancer might be linked to Roundup use.
Settlement amounts aren't pulled out of thin air. Bayer and the plaintiffs' lawyers use a sophisticated point system that's a bit like a really complex scorecard. Your cancer type matters most—aggressive forms of non-Hodgkin lymphoma score higher points than slower-moving cancers.
Age plays a huge role too. If you were diagnosed young, you typically get more money because you've lost more years of potential earnings and life. It's a harsh calculation, but that's how the legal system works.
Proving your exposure to Roundup can make or break your case. People with clear employment records showing years of occupational use generally get higher payouts than weekend gardeners with sketchy documentation. Purchase receipts, work records, and witness statements all help build your exposure story.
Here's where things get tricky: those massive jury verdicts include punitive damages designed to punish Bayer for allegedly hiding cancer risks. But appeals courts often slash these awards dramatically. The Georgia verdict's $2.1 billion included substantial punitive damages, but history suggests it will likely be reduced if Bayer appeals.
The 2020 settlement's point system created payouts ranging from $5,000 to $250,000, with most people receiving between $100,000 and $160,000. Individual trial verdicts can blow past these amounts when juries get angry about corporate behavior—but they can also result in zero if the jury sides with Bayer's defense.
The numbers tell a dramatic story about Roundup litigation. While the latest news on roundup settlement shows average payouts around $150,000, individual jury verdicts have reached billions of dollars. This massive gap reveals why some plaintiffs choose to roll the dice in court rather than accept settlement offers.
The verdict numbers are staggering. In March 2025, a Georgia jury handed down a $2.1 billion award to a single plaintiff who developed non-Hodgkin lymphoma after years of Roundup use. Just over a year earlier, a Pennsylvania jury awarded $2.25 billion (though this was later reduced to $400 million on appeal). An October 2024 Philadelphia jury awarded $78 million, and a Missouri jury in November 2023 delivered $1.56 billion (reduced to $611 million).
Compare these massive verdicts to the settlement reality. Bayer has paid approximately $11 billion to settle around 100,000 claims. That works out to an average of about $150,000 per plaintiff. The structured settlement program created payment tiers ranging from $5,000 to $250,000, with most falling in the $100,000 to $160,000 range.
The science behind these cases centers on a 2019 meta-analysis published in Mutation Research that found a 41% increased risk of non-Hodgkin lymphoma among people with high glyphosate exposure. This research has become a cornerstone of plaintiff arguments, though Bayer points to over 800 studies submitted to the EPA that they claim support glyphosate's safety.
Total jury awards across all trials have exceeded $6 billion, though many of these amounts have been reduced on appeal. For additional scientific context, research on the glyphosate cancer link provides peer-reviewed analysis of the epidemiological evidence that drives these cases.
The courtroom dynamics have shifted significantly over the past few years. While early Roundup trials resulted in massive plaintiff victories that grabbed headlines, Bayer has won 17 of the last 25 trials. This improved defense record shows that not every case is a slam dunk for plaintiffs.
Defense victories typically happen when exposure documentation is weak or when alternative causes for cancer seem more likely. The Gordon trial and the Judith Womack case in Philadelphia both ended with defense verdicts, with juries finding that the evidence didn't convincingly link Roundup to the plaintiffs' cancers.
But here's the catch—even when plaintiffs win, those eye-popping verdict amounts rarely stick. Appellate courts have consistently reduced punitive damage awards, finding them excessive compared to the actual compensatory damages. The pattern is clear: juries want to punish what they see as corporate misconduct, but appellate judges take a more conservative approach to these massive awards.
This creates a strange uncertainty for both sides. Plaintiffs can win billion-dollar verdicts that get chopped down to hundreds of millions. Bayer faces the constant threat of massive awards, even knowing many will be reduced. This unpredictability has fueled ongoing settlement negotiations and pushed Bayer to explore more definitive ways to end the litigation.
Every massive jury verdict puts enormous pressure on Bayer to settle remaining cases. The $2.1 billion Georgia verdict in March 2025 caused Bayer's stock to drop nearly 9% in a single day. When individual trial outcomes can move your stock price that dramatically, settlement starts looking more attractive.
Bayer's stock has plummeted nearly 70% since they acquired Monsanto in 2018, and these continued verdicts aren't helping. Each billion-dollar award generates negative headlines and reminds investors that this litigation nightmare isn't over. This financial pressure gives plaintiffs' attorneys significant leverage in settlement talks.
The company has set aside $5.9 billion in legal reserves for pending cases, but some analysts question whether that's enough. If average trial verdicts continue to dwarf average settlement amounts, and more plaintiffs choose to go to trial rather than settle, those reserves could prove inadequate.
Bayer has responded by ramping up lobbying efforts. The company is pushing for state and federal legislation that would limit failure-to-warn claims, arguing that EPA labeling requirements should preempt state law claims. Several states, including Iowa and Missouri, have considered bills that would provide such protection to pesticide manufacturers.
The verdict impact has created a cycle where each large award makes settlement more likely for future cases, but also raises plaintiff expectations about what their cases might be worth. It's a delicate balance that continues to shape how the latest news on roundup settlement negotiations unfold.
If you're wondering whether you have a valid Roundup claim, the latest news on roundup settlement criteria shows that qualifying isn't as complicated as you might think—but it does require meeting specific requirements.
The main hurdle is proving exposure of at least 150 hours to Roundup over your lifetime. This might sound like a lot, but it adds up quickly if you used Roundup regularly for yard work, farming, or professional landscaping. Some attorneys will consider cases with less exposure if you have really strong documentation.
Your cancer diagnosis needs to be one of the types that research has linked to glyphosate exposure. The strongest cases involve non-Hodgkin's lymphoma and its subtypes, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). Multiple myeloma cases have also seen significant success in recent trials.
Here's something crucial: you typically have one to three years from your diagnosis date to file a claim, depending on your state's statute of limitations. Some states use a "findy rule" that starts the clock when you learned about the potential connection between Roundup and your cancer, but don't count on this—time is often shorter than people realize.
Settlement amounts currently range from $5,000 to $250,000 using the established point matrix system, with most payouts landing around $150,000. However, individual negotiations can sometimes push beyond these ranges, especially when you have compelling exposure documentation and a severe diagnosis.
Kenneth Feinberg, the Special Master overseeing many settlements, weighs the strength of your documentation against established criteria. His decisions carry significant weight in determining final compensation amounts, which is why building a solid case file matters so much.
For comprehensive guidance on what documentation you'll need, check out our detailed breakdown of lawsuit requirements.
While blood cancers remain the strongest foundation for Roundup claims, researchers are uncovering potential connections to other health problems. Recent studies have found associations between glyphosate exposure and reduced birth weight in newborns, suggesting the health impacts might be broader than initially understood.
Thyroid cancer cases are increasingly making their way through the courts, though these face tougher challenges in proving causation. Some attorneys are also exploring potential links to neurodegenerative diseases, but these cases are still in early development stages.
An interesting development involves the surfactant ingredients in Roundup, particularly something called POEA (polyethoxylated tallow amine). Some research suggests these supposedly "inert" ingredients might actually be more toxic than glyphosate itself, potentially opening doors for broader injury claims.
Multiple myeloma cases have shown particular promise in recent trials. Juries seem to find the blood cancer connection more convincing with this disease, and the fact that it typically affects older patients generates sympathy when families testify about the impact.
Think of building your Roundup case like putting together a puzzle—every piece of documentation helps complete the picture of your exposure and diagnosis.
Purchase receipts are gold when it comes to proving exposure. Home improvement stores, garden centers, and farm supply companies all keep records that can help reconstruct your Roundup buying history. Don't overlook credit card statements and store loyalty program records—these have helped many people piece together years of purchases.
If you used Roundup at work, employment records become crucial. Landscapers, farmers, groundskeepers, and municipal workers should gather employment documentation, safety training records, and any workplace reports mentioning chemical exposure. Even something as simple as a job description mentioning pesticide application can strengthen your case.
Your medical records need to clearly document your cancer diagnosis and treatment timeline. Complete pathology reports are essential, and expert medical testimony linking your specific cancer type to glyphosate exposure can make or break a case. Many attorneys work with oncologists and epidemiologists who specialize in environmental cancer causation.
Don't underestimate the power of witness testimony. Family members, coworkers, or neighbors who saw you using Roundup can provide valuable support for your exposure claims. Old photos showing you applying Roundup or empty containers in your garage might seem trivial, but they can be surprisingly persuasive evidence.
If you're ready to explore your options, our Roundup Contact Form provides a secure way to share your initial case information with experienced attorneys who understand the current landscape.
Bayer has implemented a comprehensive five-point strategy to manage and ultimately end Roundup litigation. This multi-pronged approach demonstrates the company's recognition that traditional case-by-case defense is unsustainable given the volume of claims and potential for massive verdicts.
Bayer's Five-Point Plan:
1. Supreme Court Preemption Strategy: Seeking federal preemption of state failure-to-warn claims
2. Legislative Engagement: Lobbying for state and federal laws limiting liability
3. Selective Trial Defense: Defending cases strategically while settling others
4. Product Reformulation: Transitioning residential products away from glyphosate
5. Transparency Initiatives: Maintaining public safety study webpage
The Supreme Court petition represents Bayer's most significant legal gambit. The company argues that EPA labeling requirements under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) should preempt state law failure-to-warn claims. If successful, this could eliminate the majority of pending Roundup lawsuits.
Bayer has also explored more dramatic measures, including potential Chapter 11 bankruptcy protection for its Monsanto subsidiary. The company has retained both legal advisers (Latham & Watkins) and financial consultants (AlixPartners) to evaluate this option. A bankruptcy filing would pause all pending lawsuits and force resolution through the bankruptcy court system.
The product reformulation strategy has already begun, with Bayer removing glyphosate from residential lawn and garden products sold in the United States. This move, completed in 2023, was explicitly designed to reduce future litigation exposure while maintaining that glyphosate remains safe for agricultural use.
For ongoing developments in this area, our lawsuit update page provides regular monitoring of Bayer's strategic moves.
The Supreme Court preemption battle centers on several key cases that have created a circuit split among federal appeals courts. The Hardeman and Carson cases have produced conflicting rulings on whether FIFRA preempts state law failure-to-warn claims, creating the type of legal uncertainty that often prompts Supreme Court review.
Bayer's preemption argument relies on the principle that federal agencies with specialized expertise should control product labeling, not state courts and juries. The company contends that allowing state law claims undermines the EPA's comprehensive regulatory scheme for pesticide safety.
Plaintiffs' attorneys counter that FIFRA contains a savings clause preserving state law claims for damages, and that federal preemption would leave injured consumers without recourse. They argue that the EPA's review process was influenced by Monsanto's lobbying and doesn't adequately protect public health.
The circuit split has created different legal standards in different parts of the country, with some federal courts dismissing failure-to-warn claims while others allow them to proceed. This inconsistency strengthens Bayer's argument for Supreme Court review.
A favorable Supreme Court ruling on preemption could effectively end most Roundup litigation, as failure-to-warn claims represent the core of most lawsuits. However, the Court's decision to review such cases remains uncertain, and the process could take years to resolve.
Bayer's consideration of Monsanto bankruptcy reflects the enormous financial pressure created by ongoing litigation. The $63 billion Monsanto acquisition has become one of the most expensive corporate purchases in history when litigation costs are included.
Chapter 11 bankruptcy would provide several advantages for Bayer. It would automatically stay all pending lawsuits, consolidate claims in a single forum, and potentially allow for a comprehensive settlement that binds all current and future claimants. The bankruptcy court could also approve a settlement that provides finality in a way that individual settlements cannot.
However, bankruptcy also carries significant risks. It could damage Bayer's reputation further and might not provide the litigation protection the company seeks if courts find the filing inappropriate. The Johnson & Johnson talc litigation has shown that subsidiary bankruptcies face increasing judicial skepticism.
AlixPartners and Latham & Watkins are helping Bayer evaluate whether bankruptcy would provide better outcomes than continued litigation and settlement negotiations. The decision likely depends on whether other strategies, particularly Supreme Court review, show promise for resolving the litigation.
The $5.9 billion in legal reserves may prove inadequate if more cases proceed to trial rather than settling. With individual verdicts often exceeding $100 million before reduction, even a small percentage of cases going to trial could exhaust the reserves quickly.
If you're considering filing a Roundup claim, understanding the timeline can help you plan ahead and set realistic expectations. Most cases take 18 to 36 months from start to finish, though this varies depending on whether your case settles or goes to trial.
The latest news on roundup settlement negotiations shows that many cases are resolving faster than expected, particularly those with strong documentation. However, the most complex cases with significant damages may take longer as attorneys work to maximize compensation.
Here's what typically happens during the claims process:
During the first few months, you'll have your initial consultation where an attorney evaluates your case. They'll review your medical records, exposure history, and any documentation you have about Roundup use. If your case qualifies, they'll file a complaint on your behalf.
The next phase, called findy, usually takes the longest—anywhere from 4 to 12 months. This is when both sides exchange documents, take depositions, and prepare expert witnesses. It might feel slow, but this groundwork is crucial for building a strong case.
Settlement negotiations often begin around the 12-month mark. Many cases resolve through mediation, where a neutral third party helps both sides reach an agreement. The Special Master review process adds extra time but can lead to fair settlements without the uncertainty of trial.
If your case doesn't settle, trial preparation begins. Even cases that ultimately settle often go through substantial trial prep, since being trial-ready gives your attorney more negotiating power.
Future MDL bellwether trials are scheduled throughout 2025, and their outcomes will likely influence settlement offers for pending cases. These test cases help both sides understand how juries are responding to different types of Roundup claims.
Starting a Roundup case begins with gathering your medical records and any documentation of Roundup exposure. Don't worry if you don't have purchase receipts—experienced attorneys know how to help reconstruct your exposure history using employment records, credit card statements, or witness testimony.
The complaint filing happens after your attorney confirms your case meets the basic requirements. This legal document outlines why you believe Roundup caused your cancer and what compensation you're seeking. Your attorney handles all the legal language and court procedures.
Findy represents the most intensive phase of your case. You'll likely give a deposition where the other side's attorneys ask questions about your Roundup use and medical history. While this might feel intimidating, your attorney will prepare you thoroughly beforehand.
Many courts require mediation before allowing cases to proceed to trial. This gives both sides a chance to resolve the case without the time, expense, and uncertainty of a jury trial. Successful mediation can save months and provide guaranteed compensation.
If mediation doesn't work, trial preparation begins in earnest. Your legal team will finalize witness lists, prepare exhibits, and develop strategies for presenting your case to a jury. Even at this stage, settlement remains possible right up until the trial starts.
Most Roundup settlement money is tax-free under IRC Section 104, which excludes personal injury settlements from taxable income. This includes compensation for medical bills, lost wages, pain and suffering, and other damages directly related to your cancer diagnosis and treatment.
Punitive damages can be more complicated from a tax perspective. While these awards are designed to punish corporate wrongdoing rather than compensate your injuries, they may be taxable depending on how they're structured in your settlement agreement. A tax professional can help you understand your specific situation.
Some claimants choose structured settlements that provide payments over time rather than a lump sum. This can offer tax advantages and ensure long-term financial security, especially if you're younger or have ongoing medical needs.
Before you receive your settlement check, any lien resolution must occur. Medicare, Medicaid, and private health insurers may have claims against your settlement for medical expenses they've paid. This process typically takes 60 to 90 days but is essential for clearing the way for your payout.
Attorney fees are handled on a contingency basis, meaning your lawyer only gets paid if you win. The fee percentage varies but typically ranges from 33% to 40% of your gross settlement. This arrangement ensures your attorney is motivated to get you the best possible outcome.
The escrow release process involves final paperwork and verification before funds are distributed. While waiting for your settlement check can feel frustrating after months of litigation, this final step ensures all legal requirements are met and your compensation is properly protected.
The good news is that it's not too late for many people to join the Roundup litigation, though timing is becoming increasingly important. Statute of limitations windows vary by state, typically giving you one to three years from your cancer diagnosis to file a lawsuit. However, the clock might start ticking later than you think.
Many states use what's called a "findy rule" that can extend your filing deadline. This rule recognizes that you can't file a lawsuit about something you didn't know about. So if you were diagnosed with cancer years ago but only recently learned about the potential connection to Roundup, your filing window might still be open.
The latest news on roundup settlement developments show that new cases are still being filed regularly in both federal and state courts. This tells us that attorneys are finding viable cases for people who thought they might have missed their chance.
That said, waiting too long can hurt your case in other ways. Evidence gets harder to gather, witnesses' memories fade, and documentation becomes more difficult to locate. If you're thinking about filing a claim, it's worth talking to an attorney sooner rather than later.
Courts are also becoming stricter about documentation requirements. The longer you wait, the higher the bar gets for proving your exposure to Roundup and connecting it to your cancer diagnosis.
Settlement offers are still clustering around that $150,000 midpoint that was established in the 2020 global settlement, but your individual case could be worth significantly more or less depending on several key factors.
The severity modifiers make a huge difference in what you might receive. If you have an aggressive form of non-Hodgkin lymphoma and you were diagnosed at a young age, your case could be worth much more than the average. On the flip side, if you have a slower-progressing cancer type with limited documentation of Roundup use, offers tend to be lower.
Occupational exposure cases typically receive higher offers than residential use cases. If you were a landscaper, farmer, or groundskeeper who used Roundup regularly as part of your job, and you have employment records to prove it, that documentation carries significant weight in settlement negotiations.
The timing and location of your case also matter. Cases filed in state courts known for large jury awards often receive higher settlement offers than those in federal court. Bayer tends to offer more money as trial dates get closer, especially in plaintiff-friendly venues.
Recent settlements have ranged from as low as $5,000 for cases with weak documentation to over $250,000 for strong occupational exposure cases with aggressive cancers. The point matrix system continues to guide these calculations, but individual negotiations can sometimes push beyond those boundaries.
Once you reach a settlement agreement, you're typically looking at 60 to 90 days before the money actually hits your bank account. I know that feels like forever when you're dealing with medical bills and lost income, but there are important steps that have to happen first.
The biggest factor affecting timing is lien resolution. Medicare, Medicaid, and your private health insurance company may have liens against your settlement for medical expenses they've already paid. These liens have to be identified and resolved before you can receive your money. Sometimes this process uncovers liens you didn't even know existed.
Attorney fee processing and escrow account management also take time. Some settlements use centralized escrow accounts managed by the Special Master's office, while others go through individual attorney trust accounts. The more complex the settlement structure, the longer it typically takes.
If you're receiving a structured settlement with payments over time, the initial payment might come faster than a lump sum distribution. However, setting up the structured payment system can add complexity to the process.
Escrow release procedures vary depending on who's managing your specific settlement. The good news is that once all the paperwork is complete and liens are resolved, the actual money transfer usually happens quickly. Most attorneys can give you a more specific timeline once your settlement agreement is finalized.
The wait can be frustrating, especially when you're dealing with ongoing medical expenses, but these steps exist to protect you and ensure you receive the full amount you're entitled to after all obligations are met.
The latest news on roundup settlement developments in May 2025 paint a picture of a legal battle that's far from over, even as it enters a new phase. While Bayer has already paid out $11 billion to settle around 100,000 cases, the recent $2.1 billion Georgia verdict serves as a stark reminder that individual cases can still generate life-changing recoveries for those willing to take their chances at trial.
What we're seeing is essentially two parallel tracks. On one hand, you have the structured settlement process where most claimants receive around $150,000 through negotiations overseen by the Special Master. On the other hand, there's the high-stakes world of individual trials where verdicts can reach into the billions—though they often get reduced on appeal.
For anyone who used Roundup and later developed cancer, the most important thing to understand is that filing windows are still open but won't stay that way forever. Statute of limitations periods vary by state, typically running one to three years from diagnosis or findy of the potential link. The longer you wait, the harder it becomes to gather the documentation you need and the more likely you are to miss critical deadlines.
The documentation requirements haven't gotten any easier either. Strong cases still need purchase receipts, employment records, and complete medical files that clearly establish both exposure and diagnosis. If you're thinking about filing, gathering this paperwork should be your first priority.
Looking ahead, Bayer's multi-pronged strategy could reshape this entire litigation. Their Supreme Court petition seeking federal preemption could potentially eliminate most remaining cases if successful. The company's exploration of Monsanto bankruptcy represents another wild card that could force all claims into a single resolution process. These aren't distant possibilities—they're active strategies that could unfold over the next year or two.
At Justice Hero, we've watched this litigation evolve from those first shocking jury verdicts to today's complex settlement landscape. Our job has always been to cut through the legal jargon and help people understand what these developments actually mean for their lives and their families.
This case represents something bigger than just individual settlements. It's about whether companies can be held accountable when their products potentially harm people, and whether our legal system can provide meaningful justice when that harm affects hundreds of thousands of families. The latest news on roundup settlement developments show that this accountability question is still very much alive.
The numbers tell the story of just how massive this litigation has become—170,000 total claims, billions in verdicts, and a pharmaceutical giant scrambling to find a way out. It's one of the largest mass tort cases in American history, and its resolution will likely influence how similar cases are handled for decades to come.
If you're trying to figure out whether you have a case or what your options might be, our comprehensive Roundup lawsuit guide breaks down everything you need to know in plain English. Because when you're dealing with something this important, you deserve information you can actually understand.
